Product details
Catalog number ET1701-8
Price for ET1701-8
Size / count 100 µL
The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, SUMO-2, SUMO-3 and SUMO-4, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Ubiquitin and SUMO proteins utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, SUMO-2, SUMO-3 and SUMO-4 proteins localize to the nucleus. In contrast to the other SUMO proteins, SUMO-4 seems to be insensitive to sentrin-specific proteases due to the presence of Pro-90, which may impair processing to mature form and conjugation to substrates. It is suggested that defects in the gene that encodes for the SUMO-4 protein may be involved in the pathogenesis of type I diabetes.
The catalog number for SUMO4 Recombinant Rabbit Monoclonal Antibody [JJ085-01] is ET1701-8.
SUMO4 Recombinant Rabbit Monoclonal Antibody [JJ085-01] is available in the following size(s): 100 µL.
SUMO4 Recombinant Rabbit Monoclonal Antibody [JJ085-01] is currently made to order / not held in immediate stock. Contact us for lead time.
The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, SUMO-2, SUMO-3 and SUMO-4, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Ubiquitin and SUM
Molecular weight information, where applicable, is listed on the datasheet under target details, useful for confirming the correct band on western blot.
Lead times depend on the product type: custom polyclonal antibodies typically take 12-14 weeks, monoclonal antibodies 15-17 weeks, made-to-order recombinant proteins 4-8 weeks, and made-to-order recombinant antibodies 6-8 weeks. These are estimates and may shift due to production delays.
A recommended dilution range for each validated application is provided on the datasheet, but optimal dilution should be titrated for your specific experimental system, sample type, and detection method.